A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 4, 2008, Pages 673-678

  Reni, M ^a   Berardi, R ^b   Mambrini, A ^c   Pasetto, L ^d   Cereda, S ^a   Ferrari, V D ^e   Cascinu, S ^b   Cantore, M ^c   Mazza, E ^a   Grisanti, S ^e  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Ospedale Regionale Torrette   (Italy)

^c Civ Osp   (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e SPEDALI CIVILI   (Italy)

Author keywords

Chemotherapy; Gemcitabine refractory cancer; Pancreatic cancer; Second line therapy

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CARBOPLATIN; CELECOXIB; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; RALTITREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT FAILURE;

EID: 47549106754     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0653-y     Document Type: Article

References (26)

1. III HA Burris MJ Moore J Andersen 1997 Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413
2. M Reni S Cordio C Milandri 2005 Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial Lancet Oncol 6 369 376
3. M Cantore G Fiorentini G Luppi 2004 Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective randomized phase III trial of the italian society for integrated locoregional therapy in oncology J Chemother 16 34 39
4. JD Berlin P Catalano JP Thomas JW Kugler DG Haller AB Benson III 2002 Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 3270 3275
5. CMS Rocha Lima MR Green R Rotche 2004 Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 3776 3783
6. C Louvet R Labianca P Hammel 2005 Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 3509 3516
7. V Heinemann D Quietzch F Gieseler 2006 A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma J Clin Oncol 24 3946 3952
8. M Cantore C Rabbi G Fiorentini 2004 Combined irinotecan and oxalipatin in patients with advanced pre-treated pancreatic cancer Oncology 67 93 97
9. P Kozuch ML Grossbard A Barzdins 2001 Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and non crossresistant treatment for chemotherapy refractory metastatic pancreatic cancer Oncologist 6 488 495
10. M Milella A Gelibter S Di Cosimo 2004 Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma Cancer 101 133 138
11. H Oettle D Arnold M Esser D Huhn H Riess 2000 Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma Anticancer Drugs 11 635 638
12. M Reni MG Panucci P Passoni 2004 Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial Cancer Invest 22 688 696
13. JS Stehlin BC Giovanella EA Natelson 1999 A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer Int J Oncol 14 821 831
14. H Ulrich-Pur M Raderer GV Kornek 2003 Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced adenocarcinoma Br J Cancer 88 1180 1184
15. M Reni L Pasetto G Aprile 2006 Raltitrexed-eloxatin salvage chemotherapy in gemcitabine resistant metastatic pancreatic cancer Br J Cancer 94 785 791
16. A Demols M Peeters M Polus 2006 Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study Br J Cancer 94 481 485
17. Oettle H, Pelzer U, Stieler J et al (2005) Oxaliplatin/folinic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). Proc Am Soc Clin Oncol 24 (abstr 4031)
18. S Boeck K Weigang-Kohler M Fuchs 2007 Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial Ann Oncol 18 745 751
19. N Tsavaris C Kosmas H Skopelitis 2005 Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine pre-treated advanced pancreatic cancer: a phase II study Inv New Drugs 23 369 375
20. Reni M, Cereda S, Mazza E et al (2007) PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol (in press)
21. A Togawa H Yoshitomi H Ito 2007 Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study Int J Clin Oncol 12 268 273
22. MH Kulke LS Blaszkowsky DP Ryan 2007 Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer J Clin Oncol 25 4787 4792
23. V Gebbia E Maiello F Giuliani 2007 Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice Ann Oncol 18 Suppl 6 vi124 vi127
24. P Therasse SG Arbuck EA Eisenhaur 2004 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
25. A Mancuso-Petricca P Saletti MC Tronconi 2006 The efficacy of fluoropyrimidine-based second line chemotherapy in advanced and metastatic pancreatic cancer: results of an ongoing Italian/Swiss multicenter survey Ann Oncol 17 Suppl 9 ix323 (abstr. 1131P)
26. K Nakachi J Furuse H Ishii 2007 Prognostic factors in patients with gemcitabine-refractory pancreatic cancer Jap J Clin Oncol 37 114 120